{
    "id": 28654,
    "fullName": "CD37 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CD37 positive indicates the presence of the CD37 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 951,
        "geneSymbol": "CD37",
        "terms": [
            "CD37",
            "GP52-40",
            "TSPAN26"
        ]
    },
    "variant": "positive",
    "createDate": "08/30/2018",
    "updateDate": "12/31/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16707,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of CD37-positive Burkitt lymphoma cell lines in culture, and induced tumor regression in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16710,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of a CD37-positive chronic lymphocytic lymphoma cell line in culture, and induced tumor regression in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 1040,
                "name": "chronic lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16708,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of CD37-positive diffuse large B-cell lymphoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16706,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of 2 of 3 CD37-positive mantle cell lymphoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16711,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of 7 of 15 CD37-positive acute myeloid leukemia (AML) cell lines in culture, inhibited tumor growth or induced tumor regression in AML cell line xenograft models, and decreased engraftment and outgrowth in CD37-positive AML patient-derived xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15005,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Betalutin demonstrated safety and preliminary efficacy, resulted in partial remission in 43% (3/7) and complete remission in 29% (2/7) of patients with relapsed CD37-positive non-Hodgkin's B Cell Lymphoma (Blood 2014 124(21):3094).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 7393,
                "therapyName": "Betalutin",
                "synonyms": null
            },
            "indication": {
                "id": 707,
                "name": "B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12070,
                    "pubMedId": null,
                    "title": "A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma",
                    "url": "http://www.bloodjournal.org/content/124/21/3094?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16709,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of a CD37-positive follicular lymphoma cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30535,
            "profileName": "CD37 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}